Department of Pediatric Gastroenterology and Hepatology, Clinical Hospital No 1, ul. 3-go Maja 13-15, 41-800, Zabrze, Poland.
Department of Pediatrics, Institute of Medicine, University of Opole, 45-418, Opole, Poland.
World J Pediatr. 2019 Aug;15(4):332-340. doi: 10.1007/s12519-019-00267-x. Epub 2019 May 27.
Obesity and diabetes became a grooving problem in both adults and children. Many hypotheses concerned agents involved in the excessive weight gain process and it's consequences. Not only genetic or environmental factors, but also intestinal microbiome seems to play a role in the pathophysiology of this phenomenon.
A systematic review was conducted using Pubmed as the medical database source. Studies concerning connection between microbiome and metabolic disorders such as obesity and diabetes from last 10 years were analyzed.
Intestinal bacteria may be involved both in the development of obesity, and its further complications. The pro-inflammatory and immunomodulating effect of dysbiosis are possible triggers of insulin resistance and diabetes. Early interventions aimed at the microbiome, as well as attempts to modify the microbiome at later stages may become new opportunities in the prevention and treatment of obesity and carbohydrate metabolism disorders.
The gut microbiome has been shown to be an important part of the metabolic processes. The use of probiotic, prebiotics and symbiotics is promising, but requires further investigations to determine the specific metabolic effects of each bacteria strain and substance.
肥胖和糖尿病已成为成年人和儿童日益严重的问题。许多假说都涉及导致体重过度增加的因素及其后果。不仅遗传或环境因素,肠道微生物组似乎也在这一现象的病理生理学中发挥作用。
使用 Pubmed 作为医学数据库来源,进行了系统评价。分析了过去 10 年中有关微生物组与肥胖和糖尿病等代谢紊乱之间联系的研究。
肠道细菌可能参与肥胖的发展及其进一步的并发症。肠道菌群失调的促炎和免疫调节作用可能是胰岛素抵抗和糖尿病的触发因素。早期针对微生物组的干预以及在后期尝试改变微生物组可能成为肥胖和碳水化合物代谢紊乱预防和治疗的新机会。
肠道微生物组已被证明是代谢过程的重要组成部分。益生菌、益生元和合生元的使用具有广阔前景,但需要进一步研究以确定每种细菌菌株和物质的具体代谢作用。